English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background The exacerbation of malaria in sub-Saharan Africa towards the end of the 20th century accrued from amplified resistance to chloroquine and sulfadoxine-pyrimethamine (SP) the most affordable antimalaria medicines [1]. Contact with substandard antimalarial medicines probably aggravated this development [2-4]. Pressure from malaria scientists triggered extensive acceptance and implementation of artemisinin-based combination therapies (ACTs) by endemic country governments and donors [5]. All medicines carry some risk of harm and it is important to monitor their intended and unwanted effects for good evidence upon which to base an assessment of risk versus effectiveness or risk

Initial surveillance of suspected undesirable drug reactions to some Artemisinin-based combination therapies (ACTs) in Lagos, Nigeria